Higher-Dose Fluvoxamine and Time to Sustained Recovery in Ou

This randomized study examines the effect of higher-dose fluvoxamine on time to sustained recovery from mild to moderate COVID-19 or progression to severe disea

Related Keywords

Spain , Cincinnati , Ohio , United States , Quintero Cardona , Pardes Biosciences , Bristol Myers Squibb , Susanna Naggie , Eli Lilly , Johnson , Novo Nordisk , Department Of Defense , Translational Sciences , University Of Pittsburgh , Cincinnati Children Hospital Medical Center , John Hopkins University , Or Foundation , Health Insights , Us Biomedical Advanced Research Development Authority , Vanderbilt University Medical Center Clinical , Duke University School Of Medicine , Health Sciences , Astrazeneca , National Institutes Of Health , Genentech , Office Of The , Enanta Pharmaceuticals , National Center , National Institute Of Health , Government Services , Study Group , Novartis , Duke Clinical Research Institute , Biomedical Advanced Research , Arrowhead Pharmaceuticals , Pfizer , Gilead Pharmaceuticals , Patient Centered Outcomes Research Institute , World Health Organization , Group Information , Development Authority , Faron Pharmaceuticals , Boehringer Ingelheim , Endpoint Health , Gilead Sciences , Allergan , Amgen , Accelerating Coronavirus Disease , Analysis Plan , Middle Eastern , Treatment Effect Analyses , Duke University School , Drs Lindsell , Garcia Del Sol , Interest Disclosures , Cincinnati Children , Hospital Medical Center , Bioscape Digital , National Institutes , Advancing Translational Sciences , National Institute , Gala Therapeutics , Aer Therapeutics , Pioneering Medicines , Janssen Pharmaceutical , Precision Bioscience , Penn State , Advanced Research , Tunnell Government Services , Silverback Therapeutics , Vir Biotechnology , Personal Health Insights , Bristol Myers , Assistant Secretary , Translational Science Award ,